Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hypophosphatemia Kidney Transplantation Metabolic Diseases Nutritional and Metabolic Diseases Phosphorus Metabolism Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Stanford University

Stanford, California, 94304, United States

Location status: Recruiting

Location contact

Pari Waghela, MS

CONTACT

[email protected]

650-724-8441

Stephan Busque, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult kidney transplant patients.
No known contraindications to Dipyridamole

Exclusion criteria

Contraindications to Dipyridamole.
Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Treatment and study plan

Dipyridamole 75 MG

Drug

Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.

Primary outcomes

Change in Serum Phosphorus Levels After Dipyridamole Administration

Time frame: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio

This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Feb 13, 2025
Registry last updated: Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed